{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:18:33Z","timestamp":1793755113110,"version":"4.6.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc","award":["G0505124"],"award-info":[{"award-number":["G0505124"]}]},{"name":"University of Houston New Investigator Award"},{"name":"NIH NIAID"},{"DOI":"10.13039\/100000060","name":"National Institute Allergy and Infectious diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01AI139261"],"award-info":[{"award-number":["2R01AI139261"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI141349"],"award-info":[{"award-number":["T32 AI141349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is an urgent need to develop new antimicrobials effective intravenously for Clostridioides difficile infection (CDI). Omadacycline is an aminomethylcycline tetracycline available orally and intravenously with potent in vitro activity against C. difficile and a low propensity to cause CDI. The purpose of this study was to assess the safety, faecal pharmacokinetics, microbiome and bile acid changes in healthy subjects given a course of intravenous omadacycline with oral omadacycline step down after 5 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Phase 1, open-label study was conducted in healthy volunteers 18\u201340\u2005years. Subjects received a 5-day course of omadacycline given intravenously followed by 5\u2005days of oral omadacycline. Stool samples were analysed for omadacycline concentrations, gut microbiome changes and bile acid changes from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight healthy volunteers aged 30\u200a\u00b1\u200a4\u2005years (50% Female) were recruited and all completed therapy. All subjects had detectable omadacycline stool concentrations after 48\u2005hours of intravenous dosing and averaged 195\u200a\u00b1\u200a97\u2005\u00b5g\/g (mean\u200a\u00b1\u200aSD) by day 5. Omadacycline concentrations increased rapidly after the start of oral therapy on day 6 with average concentrations of 854\u200a\u00b1\u200a404\u2005\u00b5g\/g of stool by day 10. Microbiome and bile acid evaluations showed preservation of key microbiome taxa that confer health benefit and preservation of bile acid homeostasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intravenous omadacycline followed by oral step-down administration in healthy adults achieved high faecal concentrations while preserving key bacterial species and bile acid homeostasis in the gut. These findings support Phase 2 studies directed towards the development of omadacycline as a CDI-targeted antibiotic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf278","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T11:40:55Z","timestamp":1754739655000},"page":"2719-2726","source":"Crossref","is-referenced-by-count":3,"title":["Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial"],"prefix":"10.1093","volume":"80","author":[{"given":"Jinhee","family":"Jo","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis J","family":"Carlson","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Translational Sciences, The University of Texas at Austin College of Pharmacy , San Antonio, TX ,","place":["USA"]},{"name":"Pharmacotherapy Education and Research Center, The University of Texas Health Science Center at San Antonio , San Antonio, TX ,","place":["USA"]},{"name":"Department of Pharmacotherapy and Pharmacy Services, University Hospital , San Antonio, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Williamson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases, Wake Forest University School of Medicine , Winston-Salem, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda T","family":"Belin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases, Wake Forest University School of Medicine , Winston-Salem, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Horvath","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Baylor College of Medicine; \u00a0 Houston, TX ,","place":["USA"]},{"name":"Texas Children\u2019s Microbiome Center, Department of Pathology, Texas Children\u2019s Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigmund J","family":"Haidacher","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Baylor College of Medicine; \u00a0 Houston, TX ,","place":["USA"]},{"name":"Texas Children\u2019s Microbiome Center, Department of Pathology, Texas Children\u2019s Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e9nie","family":"Bass\u00e8res","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurshida","family":"Begum","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Jahangir","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-7503","authenticated-orcid":false,"given":"Kevin W","family":"Garey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2025100314222096800_dkaf278-B1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"key":"2025100314222096800_dkaf278-B2","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100314222096800_dkaf278-B3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/ciab718","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025100314222096800_dkaf278-B4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12879-023-08096-0","article-title":"The burden of CDI in the United States: a multifactorial challenge","volume":"23","author":"Feuerstadt","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2025100314222096800_dkaf278-B5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025100314222096800_dkaf278-B6","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1038\/s41467-023-39429-x","article-title":"Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile","volume":"14","author":"Olaitan","year":"2023","journal-title":"Nat Commun"},{"key":"2025100314222096800_dkaf278-B7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1055\/s-0041-1740973","article-title":"Fulminant Clostridioides difficile infection: a review of treatment options for a life-threatening infection","volume":"43","author":"Carlson","year":"2022","journal-title":"Semin Respir Crit Care Med"},{"key":"2025100314222096800_dkaf278-B8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/cid\/civ409","article-title":"The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection","volume":"61","author":"Rokas","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025100314222096800_dkaf278-B9","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/ciad792","article-title":"A randomized, double-blind, Phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile infection: clinical outcomes with microbiome and metabolome correlates of response","volume":"78","author":"Okhuysen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025100314222096800_dkaf278-B10","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1093\/jac\/dkaa364","article-title":"A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects","volume":"75","author":"Garey","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025100314222096800_dkaf278-B11","doi-asserted-by":"publisher","first-page":"e00522-20","DOI":"10.1128\/AAC.00522-20","article-title":"In vitro activity of omadacycline, a new tetracycline analog, and comparators against Clostridioides difficile","volume":"64","author":"Begum","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100314222096800_dkaf278-B12","doi-asserted-by":"publisher","first-page":"e01581-18","DOI":"10.1128\/AAC.01581-18","article-title":"Omadacycline gut microbiome exposure does not induce Clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial, and distal human colon","volume":"63","author":"Moura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100314222096800_dkaf278-B13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a Phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O'Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025100314222096800_dkaf278-B14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O'Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100314222096800_dkaf278-B15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100314222096800_dkaf278-B16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/infdis\/jiad537","article-title":"Fecal pharmacokinetics and gut microbiome effects of oral omadacycline versus vancomycin in healthy volunteers","volume":"229","author":"Jo","year":"2024","journal-title":"J Infect Dis"},{"key":"2025100314222096800_dkaf278-B17","doi-asserted-by":"publisher","first-page":"124057","DOI":"10.1016\/j.jchromb.2024.124057","article-title":"Development and validation of LC-MS\/MS for quantifying omadacycline from stool for gut microbiome studies","volume":"1236","author":"Hu","year":"2024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025100314222096800_dkaf278-B18","doi-asserted-by":"publisher","first-page":"e0199810","DOI":"10.1371\/journal.pone.0199810","article-title":"Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin","volume":"13","author":"Thorpe","year":"2018","journal-title":"PLoS ONE"},{"key":"2025100314222096800_dkaf278-B19","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1128\/AEM.66.10.4571-4574.2000","article-title":"A PCR assay to discriminate human and ruminant feces on the basis of host differences in Bacteroides-Prevotella genes encoding 16S rRNA","volume":"66","author":"Bernhard","year":"2000","journal-title":"Appl Environ Microbiol"},{"issue":"Suppl 2","key":"2025100314222096800_dkaf278-B20","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025100314222096800_dkaf278-B21","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1128\/AEM.68.11.5445-5451.2002","article-title":"Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces","volume":"68","author":"Matsuki","year":"2002","journal-title":"Appl Environ Microbiol"},{"key":"2025100314222096800_dkaf278-B22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1086\/597476","article-title":"Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection","volume":"199","author":"Jiang","year":"2009","journal-title":"J Infect Dis"},{"key":"2025100314222096800_dkaf278-B23","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1128\/AEM.70.6.3575-3581.2004","article-title":"Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota","volume":"70","author":"Bartosch","year":"2004","journal-title":"Appl Environ Microbiol"},{"key":"2025100314222096800_dkaf278-B24","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1128\/AEM.01043-13","article-title":"Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq illumina sequencing platform","volume":"79","author":"Kozich","year":"2013","journal-title":"Appl Environ Microbiol"},{"key":"2025100314222096800_dkaf278-B25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41596-022-00767-7","article-title":"Interrogation of the mammalian gut-brain axis using LC-MS\/MS-based targeted metabolomics with in vitro bacterial and organoid cultures and in vivo gnotobiotic mouse models","volume":"18","author":"Horvath","year":"2023","journal-title":"Nat Protoc"},{"key":"2025100314222096800_dkaf278-B26","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2010"},{"key":"2025100314222096800_dkaf278-B27","doi-asserted-by":"publisher","first-page":"e1009442","DOI":"10.1371\/journal.pcbi.1009442","article-title":"Multivariable association discovery in population-scale meta-omics studies","volume":"17","author":"Mallick","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2025100314222096800_dkaf278-B28","doi-asserted-by":"publisher","first-page":"e01784-16","DOI":"10.1128\/AAC.01784-16","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100314222096800_dkaf278-B29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nature13828","article-title":"Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile","volume":"517","author":"Buffie","year":"2015","journal-title":"Nature"},{"key":"2025100314222096800_dkaf278-B30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J Lipid Res"},{"key":"2025100314222096800_dkaf278-B31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2025100314222096800_dkaf278-B32","doi-asserted-by":"publisher","first-page":"s15","DOI":"10.5604\/01.3001.0010.5672","article-title":"The role of the gut microbiota in bile acid metabolism","volume":"16","author":"Ramirez-Perez","year":"2017","journal-title":"Ann Hepatol"},{"key":"2025100314222096800_dkaf278-B33","doi-asserted-by":"publisher","first-page":"e0045522","DOI":"10.1128\/msystems.00455-22","article-title":"Identification and characterization of major bile acid 7alpha-dehydroxylating bacteria in the human gut","volume":"7","author":"Kim","year":"2022","journal-title":"mSystems"},{"key":"2025100314222096800_dkaf278-B34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12915-019-0699-4","article-title":"The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health","volume":"17","author":"Waters","year":"2019","journal-title":"BMC Biol"},{"key":"2025100314222096800_dkaf278-B35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41564-023-01570-0","article-title":"Gut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids","volume":"9","author":"Liu","year":"2024","journal-title":"Nat Microbiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/10\/2719\/64025501\/dkaf278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/10\/2719\/64025501\/dkaf278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:22:33Z","timestamp":1759515753000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/10\/2719\/8232293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,8,12]]},"published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf278","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,12]]}}}